The treatment of multiple myeloma has undergone significant changes and has resulted in
the achievement of molecular remissions, the prolongation of remission duration, and …

Multiple myeloma is the second most common hematologic malignancy affecting terminally
differentiated plasma cells. Although high-dose chemotherapy and autologous stem cell …

Multiple myeloma (MM) accounts for 1% of all cancers and∼ 10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving
survival, attention is increasingly focusing on ease of administration and toxicity profile …

Natural killer (NK) cells are innate lymphocytes that are capable of eliminating tumor cells
and are therefore used for cancer therapy. Although many early investigators used …

IL-6 signaling plays a prominent role in tumorigenesis and metastasis. In this review we
discuss the recent evidence describing the tumor intrinsic and extrinsic functions of this …

Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally
infected or cancerous cells through targeted cytotoxicity and further assisting in the immune …

Bortezomib is the first proteasome inhibitor approved for the therapy of multiple myeloma
(MM). Although Bortezomib has renovated the treatment of MM, a considerable proportion of …

Multiple myeloma (MM) is a plasma cell cancer with poor survival, characterized by the
expansion of multiple myeloma cells (MMCs) in the bone marrow. Using a microarray-based …

Proper cell cycle progression through the interphase and mitosis is regulated by coordinated
activation of important cell cycle proteins (including cyclin-dependent kinases and mitotic …